Whether in metastatic melanoma, lung cancer, kidney cancer, or others, treatment with PD-1/PD-L1 or CTLA-4 inhibitors often results in stable or improved PROs when compared head-to-head with chemotherapy, targeted drugs, or placebo observation. This evidence concerns the gene CD274 and lung cancer.